His primary scientific interests are in Internal medicine, Melanoma, Immunology, Oncology and Ipilimumab. His work carried out in the field of Internal medicine brings together such families of science as Gastroenterology and Surgery. His Melanoma research is multidisciplinary, incorporating elements of Mutation, Cancer, Skin cancer and CD8.
His studies deal with areas such as Keratinocyte, Histamine H4 receptor and Histamine as well as Immunology. His study in Oncology is interdisciplinary in nature, drawing from both Binimetinib, Vemurafenib and Neuroblastoma RAS viral oncogene homolog. His Ipilimumab research is multidisciplinary, incorporating perspectives in Immune checkpoint, Retrospective cohort study, Cutaneous melanoma and Adjuvant therapy.
Ralf Gutzmer spends much of his time researching Internal medicine, Melanoma, Oncology, Immunology and Histamine. Ralf Gutzmer interconnects Gastroenterology and Surgery in the investigation of issues within Internal medicine. His study in Melanoma focuses on Binimetinib in particular.
His research investigates the link between Oncology and topics such as Vemurafenib that cross with problems in Dermatology. His Histamine study integrates concerns from other disciplines, such as Histamine receptor, Receptor and Histamine H4 receptor, Histamine H2 receptor. Pembrolizumab is closely connected to Nivolumab in his research, which is encompassed under the umbrella topic of Ipilimumab.
His scientific interests lie mostly in Internal medicine, Oncology, Melanoma, In patient and Adverse effect. His Internal medicine course of study focuses on Placebo and Adjuvant therapy and Hazard ratio. His study on Oncology also encompasses disciplines like
His Melanoma study combines topics in areas such as Immune checkpoint, Cancer, Targeted therapy, Skin cancer and V600E. His research in Adverse effect intersects with topics in Basal cell carcinoma, Toxicity and Standard treatment. His work in Ipilimumab tackles topics such as Myositis which are related to areas like Myasthenia gravis.
Ralf Gutzmer mainly investigates Internal medicine, Oncology, Adverse effect, Melanoma and Nivolumab. His study looks at the intersection of Internal medicine and topics like Placebo with Adjuvant therapy and Cancer. His Oncology research is multidisciplinary, relying on both Tolerability, MEK inhibitor, Radiation therapy and Phases of clinical research.
In his research, Standard treatment, Discontinuation and Trametinib is intimately related to Vemurafenib, which falls under the overarching field of MEK inhibitor. His Melanoma study incorporates themes from V600E and Targeted therapy. His Nivolumab research incorporates elements of Ipilimumab and Myositis.
This overview was generated by a machine learning system which analysed the scientist’s body of work. If you have any feedback, you can contact us here.
Dabrafenib in BRAF-mutated metastatic melanoma: a multicentre, open-label, phase 3 randomised controlled trial
Axel Hauschild;Jean Jacques Grob;Lev V. Demidov;Thomas Jouary.
The Lancet (2012)
Nivolumab versus chemotherapy in patients with advanced melanoma who progressed after anti-CTLA-4 treatment (CheckMate 037): a randomised, controlled, open-label, phase 3 trial.
Jeffrey S Weber;Sandra P D'Angelo;David Minor;F Stephen Hodi.
Lancet Oncology (2015)
Genomic correlates of response to CTLA-4 blockade in metastatic melanoma
Eliezer M. Van Allen;Eliezer M. Van Allen;Diana Miao;Diana Miao;Bastian Schilling;Sachet A. Shukla;Sachet A. Shukla.
Adjuvant Pembrolizumab versus Placebo in Resected Stage III Melanoma
Alexander M.M. Eggermont;Christian U. Blank;Mario Mandala;Georgina V. Long.
The New England Journal of Medicine (2018)
The Genetic Landscape of Clinical Resistance to RAF Inhibition in Metastatic Melanoma
Eliezer M. Van Allen;Eliezer M. Van Allen;Nikhil Wagle;Nikhil Wagle;Antje Sucker;Daniel J. Treacy.
Cancer Discovery (2014)
Encorafenib plus binimetinib versus vemurafenib or encorafenib in patients with BRAF-mutant melanoma (COLUMBUS): a multicentre, open-label, randomised phase 3 trial
Reinhard Dummer;Paolo A Ascierto;Helen J Gogas;Ana Arance.
Lancet Oncology (2018)
Cutaneous, gastrointestinal, hepatic, endocrine, and renal side-effects of anti-PD-1 therapy.
Lars Hofmann;Andrea Forschner;Carmen Loquai;Simone M. Goldinger.
European Journal of Cancer (2016)
Neurological, respiratory, musculoskeletal, cardiac and ocular side-effects of anti-PD-1 therapy.
Lisa Zimmer;Simone M. Goldinger;Lars Hofmann;Carmen Loquai.
European Journal of Cancer (2016)
Baseline Biomarkers for Outcome of Melanoma Patients Treated with Pembrolizumab.
Benjamin Weide;Alexander Martens;Jessica C. Hassel;Carola Berking.
Clinical Cancer Research (2016)
International Union of Basic and Clinical Pharmacology. XCVIII. Histamine Receptors
Pertti Panula;Paul L. Chazot;Marlon Cowart;Ralf Gutzmer.
Pharmacological Reviews (2015)
If you think any of the details on this page are incorrect, let us know.
We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below: